Bristol Myers Squibb (BMY) Revenue (2009 - 2026)

Bristol Myers Squibb has disclosed Revenue across 18 years of filings, most recently posting $11.5 billion for Q1 2026.

• In Q1 2026, Revenue rose 2.57% year-over-year to $11.5 billion; the TTM figure through Mar 2026 stood at $48.5 billion (up 1.78% YoY), while the FY2025 annual figure was $48.2 billion, changed 0.22% from the prior year.
• Revenue eased to $11.5 billion in Q1 2026, from $12.5 billion in the prior quarter.
• Over the last five years, Revenue for BMY reached as high as $12.5 billion in Q4 2025 and fell as low as $11.0 billion in Q3 2023.
• The 5-year median for Revenue is $11.6 billion (2022), against an average of $11.7 billion.
• Annual changes were most pronounced in 2024 — Revenue advanced 8.69% — and 2025, when it fell 5.6%.
• A 5-year view of Revenue shows it stood at $11.4 billion in 2022, then advanced by 0.62% to $11.5 billion in 2023, then advanced by 7.54% to $12.3 billion in 2024, then increased by 1.3% to $12.5 billion in 2025, then dropped by 8.1% to $11.5 billion in 2026.
• According to Business Quant data, Revenue over the past three periods registered $11.5 billion, $12.5 billion, and $12.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.